Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan
Identifieur interne : 000226 ( PascalFrancis/Checkpoint ); précédent : 000225; suivant : 000227Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan
Auteurs : Clyde Dapat [Japon] ; Hiroki Kondo [Japon] ; Isolde C. Dapat [Japon] ; Tatiana Baranovich [Japon] ; Yasushi Suzuki [Japon] ; Yugo Shobugawa [Japon] ; Kousuke Saito [Japon] ; Reiko Saito [Japon] ; Hiroshi Suzuki [Japon]Source :
- Antiviral research [ 0166-3542 ] ; 2013.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Japon.
English descriptors
- KwdEn :
Abstract
Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC50) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC50 values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC50 values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC50 values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:13-0363790Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan</title><author><name sortKey="Dapat, Clyde" sort="Dapat, Clyde" uniqKey="Dapat C" first="Clyde" last="Dapat">Clyde Dapat</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Kondo, Hiroki" sort="Kondo, Hiroki" uniqKey="Kondo H" first="Hiroki" last="Kondo">Hiroki Kondo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Dapat, Isolde C" sort="Dapat, Isolde C" uniqKey="Dapat I" first="Isolde C." last="Dapat">Isolde C. Dapat</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Baranovich, Tatiana" sort="Baranovich, Tatiana" uniqKey="Baranovich T" first="Tatiana" last="Baranovich">Tatiana Baranovich</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Yasushi" sort="Suzuki, Yasushi" uniqKey="Suzuki Y" first="Yasushi" last="Suzuki">Yasushi Suzuki</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Shobugawa, Yugo" sort="Shobugawa, Yugo" uniqKey="Shobugawa Y" first="Yugo" last="Shobugawa">Yugo Shobugawa</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Kousuke" sort="Saito, Kousuke" uniqKey="Saito K" first="Kousuke" last="Saito">Kousuke Saito</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Reiko" sort="Saito, Reiko" uniqKey="Saito R" first="Reiko" last="Saito">Reiko Saito</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Hiroshi" sort="Suzuki, Hiroshi" uniqKey="Suzuki H" first="Hiroshi" last="Suzuki">Hiroshi Suzuki</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>School of Nursing, Niigata Seiryo University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0363790</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0363790 INIST</idno><idno type="RBID">Pascal:13-0363790</idno><idno type="wicri:Area/PascalFrancis/Corpus">000197</idno><idno type="wicri:Area/PascalFrancis/Curation">001C30</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000226</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000226</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan</title><author><name sortKey="Dapat, Clyde" sort="Dapat, Clyde" uniqKey="Dapat C" first="Clyde" last="Dapat">Clyde Dapat</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Kondo, Hiroki" sort="Kondo, Hiroki" uniqKey="Kondo H" first="Hiroki" last="Kondo">Hiroki Kondo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Dapat, Isolde C" sort="Dapat, Isolde C" uniqKey="Dapat I" first="Isolde C." last="Dapat">Isolde C. Dapat</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Baranovich, Tatiana" sort="Baranovich, Tatiana" uniqKey="Baranovich T" first="Tatiana" last="Baranovich">Tatiana Baranovich</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Yasushi" sort="Suzuki, Yasushi" uniqKey="Suzuki Y" first="Yasushi" last="Suzuki">Yasushi Suzuki</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Shobugawa, Yugo" sort="Shobugawa, Yugo" uniqKey="Shobugawa Y" first="Yugo" last="Shobugawa">Yugo Shobugawa</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Kousuke" sort="Saito, Kousuke" uniqKey="Saito K" first="Kousuke" last="Saito">Kousuke Saito</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Reiko" sort="Saito, Reiko" uniqKey="Saito R" first="Reiko" last="Saito">Reiko Saito</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Hiroshi" sort="Suzuki, Hiroshi" uniqKey="Suzuki H" first="Hiroshi" last="Suzuki">Hiroshi Suzuki</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>School of Nursing, Niigata Seiryo University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Niigata</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Half maximal inhibitory concentration</term><term>Influenza</term><term>Japan</term><term>Laninamivir</term><term>Neuraminidase inhibitor</term><term>Oseltamivir</term><term>Peramivir</term><term>Profile</term><term>Sensitivity</term><term>Zanamivir</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Inhibiteur neuraminidase</term><term>Sensibilité</term><term>Profil</term><term>Grippe</term><term>Japon</term><term>Oséltamivir</term><term>Zanamivir</term><term>Péramivir</term><term>Antiviral</term><term>Pandémie</term><term>Concentration inhibitrice 50</term><term>Laninamivir</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Japon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC<sub>50</sub>) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC<sub>50</sub> values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC<sub>50</sub> values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC<sub>50</sub> values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0></fA01><fA02 i1="01"><s0>ARSRDR</s0></fA02><fA03 i2="1"><s0>Antivir. res.</s0></fA03><fA05><s2>99</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan</s1></fA08><fA11 i1="01" i2="1"><s1>DAPAT (Clyde)</s1></fA11><fA11 i1="02" i2="1"><s1>KONDO (Hiroki)</s1></fA11><fA11 i1="03" i2="1"><s1>DAPAT (Isolde C.)</s1></fA11><fA11 i1="04" i2="1"><s1>BARANOVICH (Tatiana)</s1></fA11><fA11 i1="05" i2="1"><s1>SUZUKI (Yasushi)</s1></fA11><fA11 i1="06" i2="1"><s1>SHOBUGAWA (Yugo)</s1></fA11><fA11 i1="07" i2="1"><s1>SAITO (Kousuke)</s1></fA11><fA11 i1="08" i2="1"><s1>SAITO (Reiko)</s1></fA11><fA11 i1="09" i2="1"><s1>SUZUKI (Hiroshi)</s1></fA11><fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="02"><s1>School of Nursing, Niigata Seiryo University</s1><s2>Niigata</s2><s3>JPN</s3><sZ>9 aut.</sZ></fA14><fA20><s1>261-269</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18839</s2><s5>354000501076070090</s5></fA43><fA44><s0>0000</s0><s1>© 2013 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1 p.1/4</s0></fA45><fA47 i1="01" i2="1"><s0>13-0363790</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Antiviral research</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC<sub>50</sub>) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC<sub>50</sub> values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC<sub>50</sub> values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC<sub>50</sub> values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC02 i1="02" i2="X"><s0>002B05C02C</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Inhibiteur neuraminidase</s0><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Neuraminidase inhibitor</s0><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Inhibidor neuraminidas</s0><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Sensibilité</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Sensitivity</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sensibilidad</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Profil</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Profile</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Perfil</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Grippe</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Influenza</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Gripe</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Japon</s0><s2>NG</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Japan</s0><s2>NG</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Japón</s0><s2>NG</s2><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Oséltamivir</s0><s2>NK</s2><s2>FR</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Oseltamivir</s0><s2>NK</s2><s2>FR</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Oseltamivir</s0><s2>NK</s2><s2>FR</s2><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Zanamivir</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Zanamivir</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Zanamivir</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Péramivir</s0><s2>FR</s2><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Peramivir</s0><s2>FR</s2><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Peramivir</s0><s2>FR</s2><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Antiviral</s0><s5>23</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Antiviral</s0><s5>23</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Antiviral</s0><s5>23</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Pandémie</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Concentration inhibitrice 50</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Half maximal inhibitory concentration</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Laninamivir</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Laninamivir</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Laninamivir</s0><s4>CD</s4><s5>97</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Asie</s0><s2>NG</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Asia</s0><s2>NG</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Asia</s0><s2>NG</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Exo-α-sialidase</s0><s2>FE</s2><s5>37</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Exo-α-sialidase</s0><s2>FE</s2><s5>37</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Exo-α-sialidase</s0><s2>FE</s2><s5>37</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Glycosidases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Glycosidases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Glycosidases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Glycosylases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Glycosylases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Glycosylases</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>38</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>38</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>38</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Dérivé du cyclopentane</s0><s5>39</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Cyclopentane derivatives</s0><s5>39</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Ciclopentano derivado</s0><s5>39</s5></fC07><fN21><s1>343</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Dapat, Clyde" sort="Dapat, Clyde" uniqKey="Dapat C" first="Clyde" last="Dapat">Clyde Dapat</name></noRegion><name sortKey="Baranovich, Tatiana" sort="Baranovich, Tatiana" uniqKey="Baranovich T" first="Tatiana" last="Baranovich">Tatiana Baranovich</name><name sortKey="Dapat, Isolde C" sort="Dapat, Isolde C" uniqKey="Dapat I" first="Isolde C." last="Dapat">Isolde C. Dapat</name><name sortKey="Kondo, Hiroki" sort="Kondo, Hiroki" uniqKey="Kondo H" first="Hiroki" last="Kondo">Hiroki Kondo</name><name sortKey="Saito, Kousuke" sort="Saito, Kousuke" uniqKey="Saito K" first="Kousuke" last="Saito">Kousuke Saito</name><name sortKey="Saito, Reiko" sort="Saito, Reiko" uniqKey="Saito R" first="Reiko" last="Saito">Reiko Saito</name><name sortKey="Shobugawa, Yugo" sort="Shobugawa, Yugo" uniqKey="Shobugawa Y" first="Yugo" last="Shobugawa">Yugo Shobugawa</name><name sortKey="Suzuki, Hiroshi" sort="Suzuki, Hiroshi" uniqKey="Suzuki H" first="Hiroshi" last="Suzuki">Hiroshi Suzuki</name><name sortKey="Suzuki, Yasushi" sort="Suzuki, Yasushi" uniqKey="Suzuki Y" first="Yasushi" last="Suzuki">Yasushi Suzuki</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000226 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000226 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:13-0363790
|texte= Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan
}}
| This area was generated with Dilib version V0.6.34. |  |